AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 10227008 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 mg 17 beta‐oestradiol + 2.5, 5, 10 or 15 mg dydrogesterone (orally once a day)
Number of subjects: 102
Study 8916980 — intervention group
Group type: EXPERIMENTAL
Intervention: GnRH agonist plus add-back hormone replacement therapy (HRT)
Number of subjects: 3
Study 8916980 — intervention group
Group type: EXPERIMENTAL
Intervention: 25 micrograms oestradiol patches plus continuous medroxyprogesterone acetate (5 mg)
Number of subjects: 3
Study 8916980 — intervention group
Group type: EXPERIMENTAL
Intervention: Full bone-sparing dose of oral oestradiol (2 mg daily)
Number of subjects: 3
Study 8916980 — intervention group
Group type: EXPERIMENTAL
Intervention: Gonadomimetic tibolone
Number of subjects: 3
Study 1988635 — intervention group
Group type: EXPERIMENTAL
Intervention: Miniature cesium iodide/photodiode nuclear probe (Cardioscint)
Number of subjects: 77
Study 6761854 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 290
Study 6761854 — intervention group
Group type: EXPERIMENTAL
Intervention: Methenamine hippurate
Number of subjects: 290
Study 6761854 — intervention group
Group type: EXPERIMENTAL
Intervention: Nitrofurantoin
Number of subjects: 290
Study 6761854 — intervention group
Group type: EXPERIMENTAL
Intervention: Trimethoprim
Number of subjects: 290
Study 6547543 — intervention group
Group type: EXPERIMENTAL
Intervention: Cimetidine
Number of subjects: 37
Study 6547543 — intervention group
Group type: COMPARATOR
Intervention: Pirenzepine
Number of subjects: 37
Study 31200649 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermittent hypoxic‐hyperoxic training (IHHT) combined with multimodal training intervention (MTI)
Number of subjects: 34
Study 31200649 — intervention group
Group type: COMPARATOR
Intervention: Multimodal training intervention (MTI) alone (Normoxic Group)
Number of subjects: 34
Study 29074068 — intervention group
Group type: EXPERIMENTAL
Intervention: IV metoclopramide 20mg + diphenhydramine 25mg
Number of subjects: 21
Study 30408383 — intervention group
Group type: EXPERIMENTAL
Intervention: Depot Medroxyprogesterone Acetate combined with Gonadotropin-Releasing Hormone (GnRH) analog
Number of subjects: 34
Study 30408383 — intervention group
Group type: COMPARATOR
Intervention: Depot Medroxyprogesterone Acetate alone
Number of subjects: 34
Study 25252482 — intervention group
Group type: EXPERIMENTAL
Intervention: Tamsulosin 0.4 mg/day
Number of subjects: 120
Study 25252482 — intervention group
Group type: COMPARATOR
Intervention: Control group (no Tamsulosin)
Number of subjects: 120
Study 22506940 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient-Controlled Analgesia (PCA) with 1 mg IV morphine on-demand doses
Number of subjects: 211
Study 22506940 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient-Controlled Analgesia (PCA) with 1.5 mg IV morphine on-demand doses
Number of subjects: 211
Study 22506940 — intervention group
Group type: COMPARATOR
Intervention: Non-PCA treatment (initial dose of 0.1 mg/kg IV morphine followed by physician-managed analgesia)
Number of subjects: 211
Study 21490985 — intervention group
Group type: EXPERIMENTAL
Intervention: Lift-off debonding instrument
Number of subjects: 37
Study 21490985 — intervention group
Group type: COMPARATOR
Intervention: Ligature-cutting plier
Number of subjects: 37
Study 18076256 — intervention group
Group type: EXPERIMENTAL
Intervention: 1-hour HBO exposure inspiring 100% O2 at 202.6 kPa (2.0 ATA)
Number of subjects: 18
Study 18076256 — intervention group
Group type: COMPARATOR
Intervention: 1-hour sham exposure inspiring ambient air at 121.5 kPa (1.2 ATA)
Number of subjects: 18
Study 15683500 — intervention group
Group type: EXPERIMENTAL
Intervention: Carvedilol 25 mg/day
Number of subjects: 100
Study 15683500 — intervention group
Group type: COMPARATOR
Intervention: Metoprolol 200 mg/day
Number of subjects: 100
Study 12521623 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol
Number of subjects: 184
Study 12521623 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 184
Study 10827329 — intervention group
Group type: EXPERIMENTAL
Intervention: Standardized vascular clinic (SVC) experience (4 hours)
Number of subjects: 124
Study 10827329 — intervention group
Group type: COMPARATOR
Intervention: Traditional ambulatory experience (4 hours)
Number of subjects: 124
Study 8675589 — intervention group
Group type: EXPERIMENTAL
Intervention: Parenteral estrogen (im polyestradiol phosphate, 240 mg twice monthly)
Number of subjects: 23
Study 8675589 — intervention group
Group type: COMPARATOR
Intervention: Orchidectomy
Number of subjects: 23
Study 8675589 — intervention group
Group type: EXPERIMENTAL
Intervention: Parenteral testosterone (im injections, 250 mg/week)
Number of subjects: 23
Study 2060433 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensified health education (IHE)
Number of subjects: 1139
Study 2060433 — intervention group
Group type: EXPERIMENTAL
Intervention: Clofibric acid
Number of subjects: 1139
Study 2060433 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 1139
Study 2060433 — intervention group
Group type: EXPERIMENTAL
Intervention: IHE group
Number of subjects: 1139
Study 2060433 — intervention group
Group type: EXPERIMENTAL
Intervention: IHE plus clofibric acid group
Number of subjects: 1139
Study 6359109 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol (non‐cardioselective, no ISA)
Number of subjects: 30
Study 6359109 — intervention group
Group type: EXPERIMENTAL
Intervention: Pindolol (non‐cardioselective, high ISA)
Number of subjects: 30
Study 6359109 — intervention group
Group type: EXPERIMENTAL
Intervention: Labetalol (non‐cardioselective, alpha‐blocker)
Number of subjects: 30
Study 6359109 — intervention group
Group type: COMPARATOR
Intervention: Propranolol
Number of subjects: 30
Study 6359109 — intervention group
Group type: EXPERIMENTAL
Intervention: Pindolol
Number of subjects: 30
Study 6359109 — intervention group
Group type: EXPERIMENTAL
Intervention: Labetalol
Number of subjects: 30
Study 31274334 — intervention group
Group type: EXPERIMENTAL
Intervention: Honey Bee Venom (HBV)
Number of subjects: 538
Study 31274334 — intervention group
Group type: COMPARATOR
Intervention: Control (histamine)
Number of subjects: 538
Study 28490560 — intervention group
Group type: EXPERIMENTAL
Intervention: Team-care deprescribing practice using a deprescribing guide (Beers and STOPP criteria, drug interaction checking)
Number of subjects: 0
Study 28490560 — intervention group
Group type: EXPERIMENTAL
Intervention: Team-care deprescribing practice
Number of subjects: 0
Study 25655950 — intervention group
Group type: EXPERIMENTAL
Intervention: Bupropion
Number of subjects: 16
Study 25655950 — intervention group
Group type: COMPARATOR
Intervention: MDMA
Number of subjects: 16
Study 24400934 — intervention group
Group type: EXPERIMENTAL
Intervention: Strength training (STRENGTH)
Number of subjects: 57
Study 24400934 — intervention group
Group type: EXPERIMENTAL
Intervention: Stretching (STRETCH)
Number of subjects: 57
Study 23034965 — intervention group
Group type: EXPERIMENTAL
Intervention: Long-chain n-3 PUFAs (3.36 g/d)
Number of subjects: 55
Study 23034965 — intervention group
Group type: COMPARATOR
Intervention: Control (butterfat equivalent)
Number of subjects: 55
Study 19664750 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicotine Replacement Therapy (NRT)
Number of subjects: 157
Study 19664750 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 157
Study 17963164 — intervention group
Group type: EXPERIMENTAL
Intervention: Continue GC treatment
Number of subjects: 58
Study 17963164 — intervention group
Group type: COMPARATOR
Intervention: Withdraw GC treatment
Number of subjects: 58
Study 15167190 — intervention group
Group type: EXPERIMENTAL
Intervention: Addition of a second physician during the evening shift
Number of subjects: 360
Study 15167190 — intervention group
Group type: COMPARATOR
Intervention: Control group (patients managed by internal medicine residents before the addition of a second physician)
Number of subjects: 360
Study 15167190 — intervention group
Group type: COMPARATOR
Intervention: Control group (emergency department inpatients admitted for hospitalization)
Number of subjects: 360
Study 12173164 — intervention group
Group type: EXPERIMENTAL
Intervention: Music intervention during colonoscopy
Number of subjects: 32
Study 12173164 — intervention group
Group type: COMPARATOR
Intervention: Control group (no music)
Number of subjects: 32
Study 10580204 — intervention group
Group type: EXPERIMENTAL
Intervention: CAIV-T
Number of subjects: 103
Study 10580204 — intervention group
Group type: EXPERIMENTAL
Intervention: TIV
Number of subjects: 103
Study 10580204 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 103
Study 8753947 — intervention group
Group type: EXPERIMENTAL
Intervention: Young adults (Experiment 1)
Number of subjects: 77
Study 8753947 — intervention group
Group type: EXPERIMENTAL
Intervention: Older adults (Experiment 2)
Number of subjects: 77
Study 8753947 — intervention group
Group type: EXPERIMENTAL
Intervention: Probable Alzheimer's disease patients (Experiment 3)
Number of subjects: 77
Study 8753947 — intervention group
Group type: EXPERIMENTAL
Intervention: Children aged 5-6, 9-11, and 14-16 years (Experiment 4)
Number of subjects: 77
Study 1809445 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexamethasone 1 mg each night for 4 weeks
Number of subjects: 20
Study 1809445 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 6308754 — intervention group
Group type: EXPERIMENTAL
Intervention: Mecillinam (200 mg daily for 25 days)
Number of subjects: 74
Study 6308754 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 74
Study 29842903 — intervention group
Group type: EXPERIMENTAL
Intervention: Mindfulness-based stress reduction (MBSR)
Number of subjects: 177
Study 29842903 — intervention group
Group type: COMPARATOR
Intervention: HIV disease self‐management skills group (Control)
Number of subjects: 177
Study 27414687 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypoxia group (seven passive 1-h exposures to normobaric hypoxia)
Number of subjects: 32
Study 27414687 — intervention group
Group type: COMPARATOR
Intervention: Control group (sham hypoxia)
Number of subjects: 32
Study 27414687 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypoxia group
Number of subjects: 32
Study 27414687 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 32
Study 23145830 — intervention group
Group type: EXPERIMENTAL
Intervention: Communication with an outgroup audience
Number of subjects: 0
Study 23145830 — intervention group
Group type: EXPERIMENTAL
Intervention: Heightened salience of intergroup competition
Number of subjects: 0
Study 23748920 — intervention group
Group type: EXPERIMENTAL
Intervention: apixaban 2.5 mg BID
Number of subjects: 151
Study 23748920 — intervention group
Group type: EXPERIMENTAL
Intervention: apixaban 5 mg BID
Number of subjects: 151
Study 23748920 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 151
Study 20555286 — intervention group
Group type: EXPERIMENTAL
Intervention: Mixed-Intensity Interval Endurance-Training (MI-ET) program
Number of subjects: 32
Study 20555286 — intervention group
Group type: COMPARATOR
Intervention: Endurance-Training (ET) program
Number of subjects: 32
Study 17939152 — intervention group
Group type: EXPERIMENTAL
Intervention: Test product (huperzine A 0.2 mg)
Number of subjects: 18
Study 17939152 — intervention group
Group type: COMPARATOR
Intervention: Reference product (huperzine A 0.2 mg)
Number of subjects: 18
Study 16125805 — intervention group
Group type: EXPERIMENTAL
Intervention: Tai Chi Chuan (TCC) training for 8 weeks
Number of subjects: 49
Study 16125805 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 49
Study 12924680 — intervention group
Group type: EXPERIMENTAL
Intervention: Motivational interviewing (MI)
Number of subjects: 208
Study 12924680 — intervention group
Group type: COMPARATOR
Intervention: Control (no MI)
Number of subjects: 208
Study 11012094 — intervention group
Group type: EXPERIMENTAL
Intervention: Docetaxel-based regimens
Number of subjects: 30
Study 11012094 — intervention group
Group type: EXPERIMENTAL
Intervention: Doxorubicin-based regimens
Number of subjects: 30
Study 11012094 — intervention group
Group type: COMPARATOR
Intervention: Both regimens
Number of subjects: 30
Study 11012094 — intervention group
Group type: EXPERIMENTAL
Intervention: Serum c-erbB2 measurements
Number of subjects: 30
Study 11012094 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with positive tissue staining
Number of subjects: 30
Study 8885067 — intervention group
Group type: EXPERIMENTAL
Intervention: Early intervention program providing long-term medical care and social work services (1991-1993 cohort)
Number of subjects: 868
Study 8885067 — intervention group
Group type: COMPARATOR
Intervention: No early intervention services (1989 cohort)
Number of subjects: 868
Study 8885067 — intervention group
Group type: EXPERIMENTAL
Intervention: Early intervention program (1991-1993 cohort)
Number of subjects: 868
Study 8885067 — intervention group
Group type: EXPERIMENTAL
Intervention: Prevalent gonorrhea condition at the time of HIV diagnosis
Number of subjects: 868
Study 8885067 — intervention group
Group type: EXPERIMENTAL
Intervention: Failure to return for scheduled post-HIV+ test counseling
Number of subjects: 868
Study 8885067 — intervention group
Group type: EXPERIMENTAL
Intervention: Active gonorrhea screening (1991-1993 period)
Number of subjects: 868
Study 1506533 — intervention group
Group type: EXPERIMENTAL
Intervention: Tapping in synchrony with the perceived structure of Gaussian noise samples
Number of subjects: 9
Study 2414844 — intervention group
Group type: EXPERIMENTAL
Intervention: Transurethral prostatectomy (TURP)
Number of subjects: 75
Study 2414844 — intervention group
Group type: COMPARATOR
Intervention: Transvesical prostatectomy (TVP)
Number of subjects: 75
Study 31892650 — intervention group
Group type: EXPERIMENTAL
Intervention: Tailored prehabilitation programme (patient education and exercise for 6-12 weeks)
Number of subjects: 150
Study 31892650 — intervention group
Group type: COMPARATOR
Intervention: Care as usual (control group)
Number of subjects: 150
Study 31892650 — intervention group
Group type: EXPERIMENTAL
Intervention: Tailored prehabilitation programme
Number of subjects: 150
Study 29394348 — intervention group
Group type: EXPERIMENTAL
Intervention: Rosuvastatin 20 mg/day for 4 weeks
Number of subjects: 247
Study 29394348 — intervention group
Group type: COMPARATOR
Intervention: No intervention (non-statin users)
Number of subjects: 247
Study 26725583 — intervention group
Group type: EXPERIMENTAL
Intervention: Nefopam 20 mg intravenous (i.v.) 30 min before surgery, followed by an i.v. infusion (5 mg/h) for 24 h
Number of subjects: 42
Study 26725583 — intervention group
Group type: EXPERIMENTAL
Intervention: Nefopam group
Number of subjects: 42
Study 26725583 — intervention group
Group type: COMPARATOR
Intervention: Control group (normal saline)
Number of subjects: 42
Study 24719175 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D levels (measured via DiaSorin radioimmunoassay)
Number of subjects: 82
Study 24719175 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D levels
Number of subjects: 82
Study 23220812 — intervention group
Group type: EXPERIMENTAL
Intervention: Dry needling
Number of subjects: 52
Study 23220812 — intervention group
Group type: COMPARATOR
Intervention: Sham dry needling (placebo)
Number of subjects: 52
Study 20350159 — intervention group
Group type: EXPERIMENTAL
Intervention: Xenogeneic collagen matrix (CM) with coronally advanced flap (CAF)
Number of subjects: 25
Study 20350159 — intervention group
Group type: COMPARATOR
Intervention: Connective tissue graft (CTG) with coronally advanced flap (CAF)
Number of subjects: 25
Study 18534331 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher strength 180 mT magnetic bracelets
Number of subjects: 116
Study 18534331 — intervention group
Group type: COMPARATOR
Intervention: Weak 50 mT magnetic bracelets
Number of subjects: 116
Study 15372064 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium reduction (comprehensive education and counselling about how to reduce sodium intake)
Number of subjects: 1159
Study 15372064 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium reduction
Number of subjects: 1159
Study 15372064 — intervention group
Group type: COMPARATOR
Intervention: Usual care (no dietary intervention)
Number of subjects: 1159
Study 12891223 — intervention group
Group type: EXPERIMENTAL
Intervention: Celecoxib (200 mg twice daily)
Number of subjects: 12
Study 12891223 — intervention group
Group type: COMPARATOR
Intervention: Rofecoxib (25 mg daily)
Number of subjects: 12
Study 10525564 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral L-arginine (50 mg/kg body weight)
Number of subjects: 14
Study 10525564 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 14
Study 8666597 — intervention group
Group type: EXPERIMENTAL
Intervention: Two-incision reconstruction with autogenous semitendinosus-gracilis graft (Group I)
Number of subjects: 127
Study 8666597 — intervention group
Group type: EXPERIMENTAL
Intervention: Two-incision reconstruction with autogenous patellar-ligament graft (Group II)
Number of subjects: 127
Study 8666597 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-incision reconstruction (endoscopic technique) with autogenous patellar-ligament graft (Group III)
Number of subjects: 127
Study 8381932 — intervention group
Group type: EXPERIMENTAL
Intervention: Angiotensin II (ANGII) infusion after pretreatment with lithium 750 mg
Number of subjects: 25
Study 8381932 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 25
Study 8381932 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyperinsulinaemic euglycaemic clamp in 7 non-diabetic subjects
Number of subjects: 25
Study 3113242 — intervention group
Group type: EXPERIMENTAL
Intervention: Misoprostol (800 micrograms in two or four divided doses daily)
Number of subjects: 0
Study 3113242 — intervention group
Group type: COMPARATOR
Intervention: Cimetidine (control group)
Number of subjects: 0
Study 3113242 — intervention group
Group type: EXPERIMENTAL
Intervention: Misoprostol
Number of subjects: 0
Study 29202887 — intervention group
Group type: EXPERIMENTAL
Intervention: 100-KGM (no pasta and all KGM-gel, 322 kJ (77 kcal))
Number of subjects: 16
Study 29202887 — intervention group
Group type: EXPERIMENTAL
Intervention: 50-KGM (half pasta and half KGM-gel, 1084 kJ (259 kcal))
Number of subjects: 16
Study 29202887 — intervention group
Group type: COMPARATOR
Intervention: Control (all pasta, 1849 kJ (442 kcal))
Number of subjects: 16
Study 27560971 — intervention group
Group type: EXPERIMENTAL
Intervention: Sertraline
Number of subjects: 52
Study 27560971 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 52
Study 26540313 — intervention group
Group type: EXPERIMENTAL
Intervention: Re-reading own description before identification task
Number of subjects: 208
Study 26540313 — intervention group
Group type: COMPARATOR
Intervention: No description (control group)
Number of subjects: 208
Study 23542419 — intervention group
Group type: EXPERIMENTAL
Intervention: Comprehensive exercise training (aerobic, resistance, and balance training) 3 times/week for 6 months
Number of subjects: 30
Study 23542419 — intervention group
Group type: COMPARATOR
Intervention: Stretching with minimal muscle strengthening stimuli 3 times/week for 6 months
Number of subjects: 30
Study 21988614 — intervention group
Group type: EXPERIMENTAL
Intervention: FT (new prefilled insulin pen)
Number of subjects: 242
Study 19583931 — intervention group
Group type: EXPERIMENTAL
Intervention: Xuesaitong Injection (400 mg in 250 mL 5% glucose injection, administered once daily for 6 days post-operation)
Number of subjects: 50
Study 19583931 — intervention group
Group type: COMPARATOR
Intervention: Control group (conventional anti-infection and transfusion treatment)
Number of subjects: 50
Study 17081902 — intervention group
Group type: EXPERIMENTAL
Intervention: True acupuncture starting 20 minutes before surgery
Number of subjects: 75
Study 17081902 — intervention group
Group type: COMPARATOR
Intervention: Sham acupuncture starting 20 minutes before surgery
Number of subjects: 75
Study 17081902 — intervention group
Group type: COMPARATOR
Intervention: No acupuncture
Number of subjects: 75
Study 15021850 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-report questionnaires and interview
Number of subjects: 153
Study 15021850 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinician rating
Number of subjects: 153
Study 15021850 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyclosporine levels
Number of subjects: 153
Study 15021850 — intervention group
Group type: COMPARATOR
Intervention: Electronic monitoring
Number of subjects: 153
Study 11359221 — intervention group
Group type: EXPERIMENTAL
Intervention: Regional block with 18 mL of 1% ropivacaine and oral mexiletine for the first 6 postoperative days (R + M group)
Number of subjects: 100
Study 11359221 — intervention group
Group type: EXPERIMENTAL
Intervention: Regional block and placebo (R + PL group)
Number of subjects: 100
Study 11359221 — intervention group
Group type: COMPARATOR
Intervention: Normal saline instead of ropivacaine and mexiletine (PL + M group)
Number of subjects: 100
Study 11359221 — intervention group
Group type: COMPARATOR
Intervention: Normal saline and placebo (PL + PL group)
Number of subjects: 100
Study 11359221 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 100
Study 10636072 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose combined hepatitis A and B vaccine (720 E1.U HAV antigen; 20 microg HBsAg)
Number of subjects: 100
Study 10636072 — intervention group
Group type: COMPARATOR
Intervention: Twinrix Paediatric (360 E1.U HAV antigen; 10 microg HBsAg)
Number of subjects: 100
Study 8635828 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 mg vitamin K intramuscularly
Number of subjects: 51
Study 8635828 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 mg vitamin K orally
Number of subjects: 51
Study 8635828 — intervention group
Group type: COMPARATOR
Intervention: No vitamin K
Number of subjects: 51
Study 8635828 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral vitamin K
Number of subjects: 51
Study 8635828 — intervention group
Group type: EXPERIMENTAL
Intervention: Intramuscular vitamin K
Number of subjects: 51
Study 8635828 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin K (either form)
Number of subjects: 51
Study 2697625 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled terbutaline 0.5 mg via a spacer
Number of subjects: 10
Study 2697625 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 1097840 — intervention group
Group type: EXPERIMENTAL
Intervention: 4 units of platelets (Group I)
Number of subjects: 60
Study 1097840 — intervention group
Group type: COMPARATOR
Intervention: No platelets (Group II)
Number of subjects: 60
Study 31709997 — intervention group
Group type: EXPERIMENTAL
Intervention: tranexamic acid
Number of subjects: 0